Swedish Oil and Gas Stock News

OM:G2M
OM:G2MHospitality

Gentoo Media (OM:G2M) Margin Collapse To 1.7% Tests Bullish Profit Recovery Narrative

Gentoo Media (OM:G2M) has wrapped up FY 2025 with fourth quarter revenue of €25.6 million and basic EPS of €0.07, capping a year in which trailing twelve month revenue was €98.7 million and EPS was €0.03. The company has seen quarterly revenue move from €24.8 million and an EPS loss of €0.02 in Q1 2025 to €25.6 million and EPS of €0.07 in Q4. Over the same period, trailing revenue has ranged between €98.7 million and €122.8 million, while EPS shifted from €0.18 to €0.03. For investors, the...
OM:FMM B
OM:FMM BBuilding

FM Mattsson (OM:FMM B) Margin Improvement Challenges Long Term Earnings Decline Narrative

FM Mattsson (OM:FMM B) closed out FY 2025 with fourth quarter revenue of SEK 494.7 million and basic EPS of SEK 1.04, against a backdrop of trailing twelve month revenue of SEK 1.97 billion and EPS of SEK 3.43 that came alongside a 42.3% earnings uplift over the last year. Over recent periods, revenue has moved from SEK 466.5 million and EPS of SEK 0.43 in Q4 2024 to SEK 494.7 million and EPS of SEK 1.04 in Q4 2025. Net profit margin on a trailing basis sits at 7.4% compared with 5.4% a year...
OM:VOLO
OM:VOLOIndustrials

European Growth Stocks With Insider Ownership Up To 28%

As European markets navigate volatility amid concerns about AI disruption and digest better-than-expected U.S. jobs data, the pan-European STOXX Europe 600 Index has managed to hit new highs, reflecting a resilient economic backdrop. In such an environment, growth companies with significant insider ownership can be particularly appealing as they often indicate strong internal confidence in the business's future prospects and alignment of interests with shareholders.
OM:TRUE B
OM:TRUE BSoftware

Assessing Truecaller (OM:TRUE B) Valuation After Buyback Completion And Proposed Dividend

Truecaller (OM:TRUE B) has drawn investor attention after completing a SEK 197.06 million share buyback covering 2.01% of its stock, along with a proposed dividend of SEK 0.28 per share for the 2025 financial year. See our latest analysis for Truecaller. Despite the buyback and proposed dividend, Truecaller’s recent price action has been weak, with a 7 day share price return of 28.08% and a 1 year total shareholder return of 86.89%, suggesting momentum has faded and investors are reassessing...
OM:VSURE
OM:VSURECommercial Services

Assessing Verisure (OM:VSURE) Valuation After Q4 2025 Sales Growth And Wider Net Losses

Balancing higher sales and wider losses Verisure (OM:VSURE) has drawn fresh attention after reporting Q4 and full year 2025 results, with sales of €964.7 million in the quarter and €3.7b for the year alongside wider net losses. That mix of higher revenue and larger losses gives you a lot to weigh up, especially given the stock’s recent negative returns over the month and past 3 months. Here is how those headline figures fit together. See our latest analysis for Verisure. Verisure’s latest...
OM:KARNEL B
OM:KARNEL BIndustrials

Karnell Group (OM:KARNEL B) Net Margin Expansion Tests Cautious Earnings Narratives

Karnell Group (OM:KARNEL B) has put up a busy FY 2025 so far, with Q3 revenue of SEK436 million and EPS of SEK0.88 setting the tone against a backdrop of trailing 12 month EPS of SEK2.52 and revenue of SEK1.63 billion, alongside reported earnings growth of 129.6% year on year. The company has seen quarterly revenue move from SEK356.6 million in Q3 2024 to SEK402.9 million in Q4 2024 and then SEK436 million in Q3 2025, while EPS has shifted from SEK0.55 to SEK0.57 and then SEK0.88 over the...
OM:CAMX
OM:CAMXPharmaceuticals

Why Camurus (OM:CAMX) Is Down 24.8% After Lifting 2026 Guidance and Showcasing Oxyesa Progress

Camurus AB reported its fourth-quarter and full-year 2025 results, with full-year sales rising to SEK 2,265.38 million and net income to SEK 735.57 million, while issuing 2026 guidance for revenues of SEK 2.60–2.90 billion and operating result of SEK 0.90–1.20 billion. Alongside these results, Camurus highlighted 2025 milestones including EU and UK approvals for Oxyesa in acromegaly and progress in long-acting metabolic therapies, underlining how its product pipeline and regulatory traction...